152 related articles for article (PubMed ID: 30139698)
1. Podocyturia in paediatric patients with Fabry disease.
Liern M; Collazo A; Valencia M; Fainboin A; Isse L; Costales-Collaguazo C; Ochoa F; Vallejo G; Zotta E
Nefrologia (Engl Ed); 2019; 39(2):177-183. PubMed ID: 30139698
[TBL] [Abstract][Full Text] [Related]
2. Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.
Fall B; Scott CR; Mauer M; Shankland S; Pippin J; Jefferson JA; Wallace E; Warnock D; Najafian B
PLoS One; 2016; 11(12):e0168346. PubMed ID: 27992580
[TBL] [Abstract][Full Text] [Related]
3. Podocyturia in Fabry disease.
Pereira EM; Silva AS; Labilloy A; Monte Neto JT; Monte SJ
J Bras Nefrol; 2016 Mar; 38(1):49-53. PubMed ID: 27049364
[TBL] [Abstract][Full Text] [Related]
4. Increased urinary CD80 excretion and podocyturia in Fabry disease.
Trimarchi H; Canzonieri R; Schiel A; Costales-Collaguazo C; Politei J; Stern A; Paulero M; Rengel T; Andrews J; Forrester M; Lombi M; Pomeranz V; Iriarte R; Muryan A; Zotta E; Sanchez-Niño MD; Ortiz A
J Transl Med; 2016 Oct; 14(1):289. PubMed ID: 27733175
[TBL] [Abstract][Full Text] [Related]
5. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
6. Podocyturia in Fabry disease: a 10-year follow-up.
Vujkovac B; Srebotnik Kirbiš I; Keber T; Cokan Vujkovac A; Tretjak M; Radoš Krnel S
Clin Kidney J; 2022 Feb; 15(2):269-277. PubMed ID: 35145641
[TBL] [Abstract][Full Text] [Related]
7. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
Politei J; Alberton V; Amoreo O; Antongiovanni N; Arán MN; Barán M; Cabrera G; Di Pietrantonio S; Durand C; Fainboim A; Frabasil J; Pizarro FG; Iotti R; Liern M; Perretta F; Ripeau D; Toniolo F; Trimarchi H; Rivas DV; Wallace E; Schenone AB
Pediatr Nephrol; 2018 Nov; 33(11):2095-2101. PubMed ID: 29987457
[TBL] [Abstract][Full Text] [Related]
8. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
9. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes.
Trimarchi H; Canzonieri R; Costales-Collaguazo C; Politei J; Stern A; Paulero M; González-Hoyos I; Schiel A; Rengel T; Forrester M; Lombi F; Pomeranz V; Iriarte R; Muryan A; Zotta E
Clin Kidney J; 2019 Feb; 12(1):53-60. PubMed ID: 30747154
[TBL] [Abstract][Full Text] [Related]
10. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
Moura AP; Hammerschmidt T; Deon M; Giugliani R; Vargas CR
Clin Chim Acta; 2018 Mar; 478():62-67. PubMed ID: 29274327
[TBL] [Abstract][Full Text] [Related]
11. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
12. Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients.
Martineau T; Boutin M; Côté AM; Maranda B; Bichet DG; Auray-Blais C
Clin Chim Acta; 2019 Aug; 495():67-75. PubMed ID: 30898510
[TBL] [Abstract][Full Text] [Related]
13. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
14. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study.
Madsen CV; Granqvist H; Petersen JH; Rasmussen ÅK; Lund AM; Oturai P; Sørensen SS; Feldt-Rasmussen U
Nephrol Dial Transplant; 2019 Sep; 34(9):1525-1533. PubMed ID: 30535327
[TBL] [Abstract][Full Text] [Related]
15. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
16. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
[TBL] [Abstract][Full Text] [Related]
17. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria.
Tøndel C; Bostad L; Hirth A; Svarstad E
Am J Kidney Dis; 2008 May; 51(5):767-76. PubMed ID: 18436087
[TBL] [Abstract][Full Text] [Related]
18. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
Najafian B; Svarstad E; Bostad L; Gubler MC; Tøndel C; Whitley C; Mauer M
Kidney Int; 2011 Mar; 79(6):663-670. PubMed ID: 21160462
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
[TBL] [Abstract][Full Text] [Related]
20. New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study.
Aguiar P; Azevedo O; Pinto R; Marino J; Baker R; Cardoso C; Ducla Soares JL; Hughes D
Mol Genet Metab; 2017 Jun; 121(2):162-169. PubMed ID: 28526293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
